Medline faces securities fraud probe after FDA warning and stock drops in 2026

Medline Inc. is under investigation for potential securities fraud after the FDA issued a warning about significant manufacturing violations. The company’s stock dropped 7% in June 2026 following the FDA letter and another 13% in August after Medline reported earnings losses linked to remediation efforts. Investors who suffered losses are encouraged to seek legal advice as the investigation continues. This case highlights risks related to product quality disclosures in healthcare manufacturing.

Medline's ongoing securities fraud investigation and related stock losses underline the challenges the company faces. On Pluang, MDLN trades at USD 34.08 with a slight 1-day decline of 0.03% as of Oct 26, 2026 17:02 WIB. The stock remains well below its 52-week high of USD 49.99, showing continued market caution around the health sector name.